Plant Name: Stachys plumosa
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.252E-11 | 2.725E-07 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 9.469E-08 | 2.968E-04 | BCHE, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.212E-07 | 2.968E-04 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.227E-07 | 2.968E-04 | ACHE, BCHE, DRD2, HTT, MTOR, NFKB1, PKM, SMN1, SMN2, STAT6, TP53 |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 1.579E-07 | 3.092E-04 | DRD1, DRD2, HIF1A, MTOR |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.076E-07 | 3.092E-04 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.076E-07 | 3.092E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 5.102E-07 | 4.862E-04 | ACHE, BCHE, DRD1, DRD2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.136E-07 | 4.862E-04 | ALOX15, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 1.019E-06 | 7.154E-04 | ACHE, BCHE |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.659E-06 | 1.129E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 3.054E-06 | 1.633E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.595E-06 | 1.779E-03 | HIF1A, LMNA, MTOR, TP53 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 5.565E-06 | 2.376E-03 | CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.104E-06 | 2.416E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.209E-06 | 2.883E-03 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 1.017E-05 | 3.354E-03 | DRD1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0046483; heterocycle metabolic process | 1.605E-05 | 4.723E-03 | ACHE, BCHE, CYP1A2, CYP2C19, CYP2D6, CYP3A4, HIF1A, MTOR, NFKB1, PKM, SMN1, SMN2, STAT6, TP53 |
| BP | GO:0008152; metabolic process | GO:0006725; cellular aromatic compound metabolic process | 1.776E-05 | 4.896E-03 | ACHE, BCHE, CYP1A2, CYP2D6, DRD1, DRD2, HIF1A, MTOR, NFKB1, PKM, SMN1, SMN2, STAT6, TP53 |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 2.841E-05 | 7.279E-03 | DRD1, DRD2 |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 4.013E-05 | 9.395E-03 | DRD1, DRD2, HIF1A, HTT, MTOR, PKM, SMN1, SMN2 |
| BP | GO:0050896; response to stimulus | GO:0007584; response to nutrient | 4.130E-05 | 9.566E-03 | BCHE, MTOR, PKM, TP53 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 4.196E-05 | 9.617E-03 | DRD1, MTOR, NFKB1, PKM, TP53 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.699E-08 | 1.937E-06 | CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 5.352E-07 | 2.291E-05 | PKM; TP53; HIF1A; MTOR |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.028E-07 | 2.291E-05 | CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.530E-05 | 4.360E-04 | DRD1; DRD2; NFKB1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 5.086E-05 | 1.160E-03 | CYP2D6; CYP1A2; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 9.193E-05 | 1.497E-03 | TP53; NFKB1; MTOR |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.082E-04 | 1.541E-03 | TP53; NFKB1; MTOR |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 7.201E-05 | 1.368E-03 | CYP1A2; CYP3A4; CYP2C19 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.419E-04 | 1.797E-03 | HIF1A; NFKB1; MTOR |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.818E-04 | 2.073E-03 | CYP2D6; ALOX15; CYP2C19 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.121E-04 | 2.198E-03 | TP53; HIF1A; MTOR |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.507E-04 | 3.332E-03 | LMNA; TP53; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 5.758E-04 | 4.376E-03 | HIF1A; TP53; NFKB1; MTOR |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.966E-04 | 3.478E-03 | STAT6; TP53; NFKB1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 4.996E-04 | 4.068E-03 | THPO; STAT6; MTOR |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.034E-03 | 6.382E-03 | TP53; HIF1A; MTOR |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 9.763E-04 | 6.382E-03 | DRD1; DRD2; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.064E-03 | 6.382E-03 | PKM; TP53; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.467E-03 | 8.244E-03 | NFKB1; MTOR |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.042E-03 | 6.382E-03 | PKM; MTOR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.903E-03 | 8.280E-03 | TP53; MTOR |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.624E-03 | 8.280E-03 | HIF1A; MTOR |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.064E-03 | 1.165E-02 | TP53; NFKB1; MTOR |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.733E-03 | 8.280E-03 | ALOX15; CYP2C19 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 4.516E-03 | 1.516E-02 | TP53; NFKB1; MTOR |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.961E-03 | 8.280E-03 | TP53; NFKB1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.519E-03 | 8.244E-03 | CYP1A2; CYP3A4 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.903E-03 | 8.280E-03 | STAT6; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.393E-03 | 9.406E-03 | TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.903E-03 | 8.280E-03 | CYP1A2; CYP3A4 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 2.203E-03 | 8.968E-03 | NFKB1; MTOR |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 4.521E-03 | 1.516E-02 | HIF1A; MTOR |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.302E-03 | 1.214E-02 | TP53; NFKB1 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 6.417E-03 | 1.876E-02 | PKM; CYP1A2; ALOX15; CYP2C19; CYP3A4 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 3.454E-03 | 1.231E-02 | DRD1; DRD2 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 5.245E-03 | 1.661E-02 | NFKB1; MTOR |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 6.321E-03 | 1.876E-02 | TP53; NFKB1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 7.269E-03 | 2.072E-02 | DRD1; DRD2 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 6.321E-03 | 1.876E-02 | TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 8.049E-03 | 2.185E-02 | TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 7.710E-03 | 2.144E-02 | TP53; NFKB1 |
| hsa05012 | Parkinson's disease_Homo sapiens_hsa05012 | 8.746E-03 | 2.319E-02 | DRD1; DRD2 |
| hsa03013 | RNA transport_Homo sapiens_hsa03013 | 1.262E-02 | 3.270E-02 | SMN2; SMN1 |
| hsa05034 | Alcoholism_Homo sapiens_hsa05034 | 1.361E-02 | 3.410E-02 | DRD1; DRD2 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.711E-02 | 3.981E-02 | TP53; NFKB1 |
| hsa05016 | Huntington's disease_Homo sapiens_hsa05016 | 1.570E-02 | 3.729E-02 | HTT; TP53 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.376E-02 | 3.410E-02 | TP53; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.449E-02 | 3.515E-02 | TP53; NFKB1 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.991E-03 | 1.625E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MTOR; PKM; HIF1A; TP53 |
| NA: NA | Corneal vascularity | NA | DRD2 |
| NA: NA | Coronary artery restenosis | NA | MTOR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| C00-D49: Neoplasms | Multiple myeloma | C90 | MTOR; MTOR |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| NA: NA | Peripheral vasoconstriction | NA | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR |
| NA: NA | Vomiting | NA | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; DRD1 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MTOR |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2 |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2 |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| C00-D49: Neoplasms | Bladder cancer | C67 | MTOR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; DRD2; DRD2; DRD2 |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MTOR; DRD2 |
| C00-D49: Neoplasms | Solid tumors | NA | MTOR |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2 |
| C00-D49: Neoplasms | Cancer | C00-C96 | MTOR; NFKB1; HIF1A; TP53; ACHE |
| NA: NA | Malignant essential hypertension | NA | DRD2 |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2 |
| C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | DRD2; ACHE |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | DRD2 |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2 |
| NA: NA | Hyperaemia | NA | DRD2 |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | MTOR; HIF1A |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; DRD2; DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| NA: NA | Itching | NA | DRD2 |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; DRD2; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | DRD1; DRD2; ACHE |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MTOR |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MTOR; PKM; DRD1; DRD2; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | DRD1; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; DRD2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2 |
| NA: NA | Inflammatory diseases | NA | DRD2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MTOR; DRD2 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | DRD2; ACHE; ACHE; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1 |
| C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2 |
| NA: NA | False perceptions | NA | DRD2 |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2 |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | MTOR |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2 |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | MTOR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; DRD2; DRD2; DRD2; DRD2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2 |
| NA: NA | Schizoaffective disorders | NA | DRD2 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | DRD2 |